Interest in the tetracyclines in AD raised around the early 2000s when it was found, using cell-free approaches, that tetracyclines could inhibit the aggregation of both the synthetic PrP residues 106–126 and 82–146 of human PrP and the Aβ peptide. Here, PRNP is linked to Alzheimer disease.